We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Jun 2020 - 09 Jun 2020
Virtual Venue
08 Jun 2020 - 11 Jun 2020
Virtual Venue

FDA Clears Wearable Heart and Respiratory Rate Monitor

By Michal Siman-Tov
Posted on 13 Dec 2016
Print article
Image: The SimplECG is designed to capture and transmit diagnostic data via everyday garments in an effort to monitor heart behavior and help prevent cardiac-related events (Photo courtesy of Shutterstock).
Image: The SimplECG is designed to capture and transmit diagnostic data via everyday garments in an effort to monitor heart behavior and help prevent cardiac-related events (Photo courtesy of Shutterstock).
A cardiac and respiration monitoring undergarment device has received Class II 510(k) clearance from the US Food & Drug Administration (FDA) to enable remote collection of continuous multi-channel ECG, heart rate, and respiratory rate data from a novel diagnostic nanosensor technology. The data are transferred to a web-based portal for review by a physician, by way of a mobile application.

The transformative wearable device, SimplECG, was developed by Nanowear (New York City, NY, USA), an early stage developer of cloth-based diagnostic monitoring nanosensor technology, which differentiates Nanowear in an otherwise crowded market for wearables. SimplECG will provide an easier and more patient-friendly means of capturing and transmitting diagnostic data via everyday garments in an effort to monitor heart behavior and help prevent cardiac-related events such as heart attacks. The initial version of SimplECG is iPhone-based.

"As healthcare continues to evolve and move beyond the walls of the hospital, easy-to-use and clinically validated solutions are essential to ensure patient compliance and actionable diagnostic insights for physicians and providers," said John Zimmerman, MD, Nanowear's Chief Medical Officer.

"This is a big milestone for our young company," said co-founder & CEO Venk Varadan, "The FDA's decision not only positions us for commercial opportunities in remote cardiac monitoring, but more importantly, it provides accreditation of the company's one-of-a-kind, cloth-based sensor technology as medical-grade. This is the first step and foundation of what we believe to be an extensive array of applications for our nanosensor technology – including numerous other electrical, biometric, and biochemical signals that can be measured directly from the skin without conductive gels, adhesives, or skin preparation."

Having spent the last two years focused solely on product development and the regulatory process, Nanowear will now focus its near-term efforts on product commercialization, strategic partnerships, and continued development of complementary products and applications for chronic disease states.

Related Links:
Nanowear


Print article

Channels

Microbiology

view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.